Cataford Gabrielle, Monton Laurie-Anne, Karzon Stephanie, Livernoche-Leduc Camille, Saavedra-Mitjans Mar, Potvin Marie-Julie, Bernard Francis, Burry Lisa, Arbour Caroline, Williamson David R
Faculté de pharmacie, Université de Montréal, Montreal, Quebec, Canada.
Faculté de Médecine, Université de Montréal, Montreal, Quebec, Canada.
Neurotrauma Rep. 2024 Mar 5;5(1):181-193. doi: 10.1089/neur.2023.0108. eCollection 2024.
Traumatic brain injury (TBI) survivors often suffer from agitated behaviors and will most likely receive pharmacological treatments. Choosing an optimal and safe treatment that will not interfere with neurological recovery remains controversial. By interfering with dopaminergic circuits, antipsychotics may impede processes important to cognitive recovery. Despite their frequent use, there have been no large randomized controlled studies of antipsychotics for the management of agitated behaviors during the acute TBI recovery period. We conducted a systematic review and meta-analysis of pre-clinical studies evaluating the effects of antipsychotics post-TBI on both cognitive and motor recovery. MEDLINE and Embase databases were searched up to August 2, 2023. Pre-clinical studies evaluating the effects of antipsychotics on cognitive and motor functions post-TBI were considered. Risk of bias was evaluated with the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool. We identified 15 studies including a total of 1188 rodents, mostly conducted in male Sprague-Dawley rats using cortical impact injury. The analysis revealed no consistent effect of haloperidol on motor functions, but risperidone was associated with a significant impairment in motor function on day 5 post-injury (7.05 sec; 95% confidence interval [CI]: 1.47, 12.62; I = 92%). Other atypical antipsychotics did not result in impaired motor function. When evaluating cognitive function, haloperidol- (23.00 sec; 95% CI: 17.42-28.59; I = 7%) and risperidone-treated rats (24.27 sec; 95% CI: 16.18-32.36; I = 0%) were consistently impaired when compared to controls. In studies evaluating atypical antipsychotics, no impairments were observed. Clinicians should avoid the regular use of haloperidol and risperidone, and future human studies should be conducted with atypical antipsychotics.
创伤性脑损伤(TBI)幸存者常常出现激越行为,很可能会接受药物治疗。选择一种不会干扰神经功能恢复的最佳且安全的治疗方法仍存在争议。抗精神病药物通过干扰多巴胺能回路,可能会阻碍对认知恢复至关重要的过程。尽管它们被频繁使用,但尚无关于抗精神病药物用于急性TBI恢复期激越行为管理的大型随机对照研究。我们对评估TBI后抗精神病药物对认知和运动恢复影响的临床前研究进行了系统评价和荟萃分析。检索MEDLINE和Embase数据库至2023年8月2日。纳入评估TBI后抗精神病药物对认知和运动功能影响的临床前研究。使用实验动物系统评价中心(SYRCLE)工具评估偏倚风险。我们确定了15项研究,共涉及1188只啮齿动物,大多使用皮质撞击伤在雄性斯普拉格-道利大鼠中进行。分析显示氟哌啶醇对运动功能无一致影响,但利培酮与伤后第5天运动功能显著受损相关(7.05秒;95%置信区间[CI]:1.47,12.62;I² = 92%)。其他非典型抗精神病药物未导致运动功能受损。在评估认知功能时,与对照组相比,氟哌啶醇治疗的大鼠(23.00秒;95% CI:17.42 - 28.59;I² = 7%)和利培酮治疗的大鼠(24.27秒;95% CI:16.18 - 32.36;I² = 0%)持续受损。在评估非典型抗精神病药物的研究中,未观察到损伤。临床医生应避免常规使用氟哌啶醇和利培酮,未来应使用非典型抗精神病药物开展人体研究。